Incheon: SK Bioscience Co., the biotech division of South Korea's SK Group, has inaugurated its new global research and development center in the western port city of Incheon. The facility, located in Songdo, aims to enhance the company's vaccine research capabilities, as stated by the company. According to Yonhap News Agency, the newly operational Global Research and Process Development (R and PD) Center represents a significant investment of 377.2 billion won (US$255.7 million). This facility not only serves as the company's new headquarters but also stands as the nation's largest building dedicated solely to vaccine development. SK Bioscience has expressed its commitment to conducting comprehensive research across various vaccine solutions at this site. The research center empowers SK Bioscience to manage the complete development cycle-from early-stage research to technical validation-within a single location. This integration is expected to enhance both the speed and quality of the development process. The company highlighted that the center's establishment marks a significant step in executing its mid- to long-term growth strategy. Ahn Jae-young, CEO of SK Bioscience, emphasized the strategic importance of the move to the Songdo Global R and PD Center. He remarked that the relocation is not just a mere transfer of operations but an acquisition of essential infrastructure critical for the company's future growth plans.